Md.’s MaxCyte signs commercial licensing agreement with Austrian biotech

MaxCyte Inc., a Gaithersburg cell-based therapies and life sciences company, signed a clinical and commercial licensing agreement Wednesday with Apeiron Biologics AG, a private biotechnology company specializing in the discovery, development and commercialization of novel immunotherapies for cancer and respiratory diseases. Apeiron will obtain non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *